Skip to content

Psilocybin: all studies

Page 354 of 441: studies 3,531 to 3,540 of 4,401, newest first. Back to the psilocybin overview

Research

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

American Journal of Psychiatry 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason 25 citations

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...

DOI: 10.1176/appi.ajp.20230890 (opens in new tab) 5-MEO-DMT Depression Psychedelic drugs Quick-onset treatment +3

Mushroom poisoning: An updated review

Turkish Journal of Emergency Medicine 2025 Mustafa Oğuz Tuğcan, Ayça Açıkalın 11 citations

Abstract Mushrooms have been consumed frequently worldwide since ancient times. In addition to edible and harmless species, there are also poisonous species that cause a wide range of clinical syndromes, from simple gastrointestinal (GI) irritation to death. However, it is not possible to distinguish the poisonous species from some edible species morphologically. Therefore, the unintentional...

DOI: 10.4103/tjem.tjem_129_24 (opens in new tab) Mushroom poisoning Medical emergency

Corrigendum: Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment.

Frontiers in Psychiatry 2025 Jonathan David, José Carlos Bouso, Maja Kohek et al. correction

1. In the published article, there was an error. The error was regarding the average number of ayahuasca uses in the ayahuasca group in Study 1. A correction has been made to the Results section in lines 387-390. This sentence previously stated:Briefly, on average, our study participants have used ayahuasca (mean = 69.4 ± 98.7), 6.4 times more than psilocybin (mean = 10.7 ± 15.4, U = 1378, p <...

A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.

PLoS One 2025 Sarah Kratina, Carol Strike, Robert Schwartz et al. 1 citation

Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their...

DOI: 10.1371/journal.pone.0318343 (opens in new tab) Full text (opens in new tab) Psychedelic therapy End-of-life treatment Mental health interventions Terminal illness +1

Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse

Saudi Journal of Medicine and Public Health December 31, 2024 Khalaud Naseeb Alhajry, Zahra Mohammed Sukairi, Hamidah Abdullah Lajami et al.

Background: Psychedelic-assisted therapy (PAT) is experiencing a resurgence, with expanding evidence proving its efficacy for treatment-resistant psychiatric-mental health conditions. Psychiatric-mental health nurses (PMHNs) are uniquely positioned to provide PAT due to their integrated care capabilities, yet their roles are poorly defined. Aim: This review synthesizes PAT's clinical...

DOI: 10.64483/20251153 (opens in new tab) Cinahl Leverage statistics Health care Scholarship +5

Treatment-Resistant Depression: A Comprehensive Insight of Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Psychedelic-Assisted Psychotherapy

Annals of Punjab Medical College December 31, 2024 Mohammad Ali, Urbah Viqar

Background: The phenomenon of treatment-resistant depression (TRD) remains a problem in the sphere of mental health treatment since the majority of patients do not experience positive effects while receiving traditional treatments. Newer therapies are ketamine infusion therapy for depression, transcranial magnetic stimulation, and psilocybin-assisted psychotherapy give new hope. Objective: To...

Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey

Journal of Psychoactive Drugs December 24, 2024 Omer A. Syed, Rotem Petranker, Emily C. Fewster et al. 3 citations

Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little research has examined the preferences surrounding the source of psychedelic substances. In an anonymous online survey, we collected data from 6,379 consumers of 11 different psychedelic substances from 85 different countries, exploring their preferences...

DOI: 10.1080/02791072.2024.2446445 (opens in new tab) Environmental considerations Natural sources Psychedelics Synthetic substances +3

Classic psychedelics and the treatment for alcoholism.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 20, 2024 Guilherme Lodetti, Rafael Mariano de Bitencourt, Eduardo Pacheco Rico 9 citations

Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-resistant, and no completely effective treatment model is available for chemical dependence. Classic psychedelics, such as LSD, psilocybin, and ayahuasca have been used in different clinical and pre-clinical trials, demonstrating promising...

Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.

Journal of the American Academy of Child & Adolescent Psychiatry December 19, 2024 Paul E Croarkin, Isabella Sutherland, Ming-Fen Ho 1 citation

We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."1 We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide,...

DOI: 10.1016/j.jaac.2024.12.003 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Adolescent medicine Psychiatric treatment Youth mental health

Shamans, plants, and spirits: Health and disease in the Plantocene

Etnografia. Praktyki, Teorie, Doświadczenia December 16, 2024 Anna Zadrożna

This paper explores the experiences and perspectives of people from Poland who engage with psychoactive plants, referred to by me as the Plants, such as ayahuasca, psilocybin mushrooms, and mescaline-containing cacti-for healing and personal growth. Based on fourteen in-depth interviews and analysis of online discussions, the paper examines how my interlocutors conceptualize health, disease,...

DOI: 10.26881/etno.2024.10.11 (opens in new tab) Silence Agency philosophy Narrative Indigenous +4